While Kymera Therapeutics Inc has overperformed by 0.19%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KYMR rose by 39.50%, with highs and lows ranging from $53.27 to $19.44, whereas the simple moving average jumped by 17.63% in the last 200 days.
On June 03, 2025, Morgan Stanley Upgraded Kymera Therapeutics Inc (NASDAQ: KYMR) to Overweight. A report published by B. Riley Securities on June 03, 2025, Upgraded its rating to ‘Buy’ for KYMR. BofA Securities also Upgraded KYMR shares as ‘Buy’, setting a target price of $51 on the company’s shares in a report dated June 02, 2025. Stifel Initiated an Buy rating on May 20, 2025, and assigned a price target of $55. Citigroup initiated its ‘Buy’ rating for KYMR, as published in its report on March 13, 2025. BTIG Research’s report from December 10, 2024 suggests a price prediction of $60 for KYMR shares, giving the stock a ‘Buy’ rating. BMO Capital Markets also rated the stock as ‘Market Perform’.
Analysis of Kymera Therapeutics Inc (KYMR)
Further, the quarter-over-quarter increase in sales is 114.83%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Kymera Therapeutics Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -32.17% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.49, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and KYMR is recording an average volume of 867.76K. On a monthly basis, the volatility of the stock is set at 8.84%, whereas on a weekly basis, it is put at 0.54%, with a loss of -4.03% over the past seven days. Furthermore, long-term investors anticipate a median target price of $62.32, showing growth from the present price of $46.44, which can serve as yet another indication of whether KYMR is worth investing in or should be passed over.
How Do You Analyze Kymera Therapeutics Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 18.37%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 95.94% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
KYMR shares are owned by institutional investors to the tune of 95.94% at present.
